1 July 2023 in Annals of the American Thoracic Society
Rationale: Recent randomized controlled trials did not show cardiovascular benefits of continuous positive airway pressure (CPAP) in adults with coronary artery disease (CAD) and obstructive sleep apnea (OSA) in intention-to-treat analyses. It has been argued that exclusion of patients with OSA with excessive daytime sleepiness (EDS), who may be most likely to benefit from CPAP treatment, may be a reason for the null results. Objectives: We addressed 1) the effect of concomitant EDS on adverse outcomes in patients with CAD and OSA; and 2) whether the cardiovascular benefit of CPAP adherence differs between individuals with versus without EDS. Methods: This was a secondary analysis of the RICCADSA (Randomized Intervention with CPAP in CAD and Obstructive Sleep Apnea) trial, conducted in Sweden between 2005 and 2013. Data were analyzed from 155 patients with CAD with OSA (apnea–hypopnea index ⩾ 15/h) and EDS (Epworth Sleepiness Scale score ⩾ 10), who were allocated to CPAP and 244 patients without EDS (ESS < 10), who were randomized to CPAP or no CPAP. Patients who were allocated to no CPAP or were nonadherent (CPAP usage < 4 h/night) were compared with adherent patients (CPAP usage ⩾ 4 h/night) at 1-year follow-up. Inverse probability of treatment weighting was applied to mimic randomization of EDS. The primary endpoint was the first event of repeat revascularization, myocardial infarction, stroke, or cardiovascular mortality. Results: The median follow-up was 52.2 months. The incidence of the primary endpoint did not differ significantly between the EDS versus no-EDS groups in the entire cohort. Within the adherent group, patients without EDS had a significantly decreased risk compared with patients with EDS (adjusted hazard ratio, 0.41; 95% confidence interval, 0.20–0.85; P = 0.02). Conclusions: Adverse cardiovascular outcomes did not differ by degrees of EDS for patients with CAD with OSA who were untreated or nonadherent to treatment. CPAP use, at least 4 h/night, was associated with reduced adverse outcomes in participants without EDS. Clinical trial registered with www.clinicaltrials.gov (NCT 00519597).
7 December 2017 in European Respiratory Journal
Coronary artery disease (CAD) patients with obstructive sleep apnoea (OSA) have increased risk for major adverse cardiovascular and cerebrovascular events (MACCEs) compared with CAD patients without OSA. We aimed to address if the risk is similar in both groups when OSA patients are treated.This study was a parallel observational arm of the RICCADSA randomised controlled trial, conducted in Sweden between 2005 and 2013. Patients with revascularised CAD and OSA (apnoea–hypopnoea index (AHI) ≥15 events·h−1) with daytime sleepiness (Epworth Sleepiness Scale score ≥10) were offered continuous positive airway pressure (CPAP) (n=155); CAD patients with no OSA (AHI <5 events·h−1) acted as controls (n=112), as a randomisation of sleepy OSA patients to no treatment would not be ethically feasible. The primary end-point was the first event of MACCEs. Median follow-up was 57 months.The incidence of MACCEs was 23.2% in OSA patientsversus16.1% in those with no OSA (adjusted hazard ratio 0.96, 95% CI 0.40–2.31; p=0.923). Age and previous revascularisation were associated with increased risk for MACCEs, whereas coronary artery bypass grafting at baseline was associated with reduced risk.We conclude that the risk for MACCEs was not increased in CAD patients with sleepy OSA on CPAP compared with patients without OSA.
7 April 2026 in Sleep Medicine
Obstructive sleep apnea (OSA) is associated with autonomic dysfunction and increased cardiovascular risk, but the effects of continuous positive airway pressure (CPAP) on exercise-derived autonomic responses in patients with coronary artery disease (CAD) remain unclear. This study included nonsleepy patients (Epworth Sleepiness Scale score <10) with CAD and OSA (apnea-hypopnea index ≥15 events/h) enrolled in the RICCADSA randomized controlled trial. Of 244 patients randomized at baseline, 204 (CPAP n = 100; no-CPAP n = 104) completed bicycle ergometer exercise testing at both 3 and 12 months and were included. The primary outcome was the change in 1-min heart rate recovery (HRR1) from 3 to 12 months; secondary outcomes included changes in 4-min heart rate recovery (HRR4), chronotropic response, and post-exercise recovery time. Longitudinal changes were analyzed using linear mixed-effects models adjusted for sex, body mass index (BMI), diabetes, and β-blocker use. HRR1 remained stable from 3 to 12 months in both groups (approximately 22-23 bpm), with no CPAP or time × treatment effects. HRR4 showed no differential change, remaining around 46-47 bpm. Chronotropic response was unchanged (chronotropic index approximately 0.74-0.76 in both groups). Exercise workload and peak heart rate remained stable over time and did not differ between groups. Post-exercise recovery time shortened significantly in the overall cohort (by approximately 0.3 min from 3 to 12 months) but was not CPAP-specific. Higher BMI and β-blocker use were independently associated with impaired late HRR and chronotropic response. In nonsleepy patients with CAD and OSA, CPAP does not modify exercise-derived autonomic or chronotropic responses, underscoring the need for complementary strategies targeting metabolic burden and cardiovascular conditioning.
21 May 2026 in Sleep Medicine
Obstructive sleep apnea (OSA) is highly prevalent in patients with coronary artery disease (CAD) and is associated with autonomic dysfunction and adverse cardiovascular outcomes. Exercise-derived autonomic markers provide an integrated assessment of cardiovascular autonomic regulation. Whether baseline OSA severity and longitudinal autonomic adaptation during continuous positive airway pressure (CPAP) therapy are influenced by daytime sleepiness remains unclear. In the RICCADSA cohort, 322 patients with CAD were studied, including CPAP-treated patients with moderate-to-severe OSA classified as non-sleepy (Epworth Sleepiness Scale [ESS] <10; n = 100) or sleepy (ESS ≥10; n = 130), and a non-OSA reference group (apnea-hypopnea index [AHI] <5 events/h; n = 92). Standardized exercise testing was performed at 3 and 12 months. Outcomes included heart-rate recovery at 1 and 4 min (HRR1, HRR4), chronotropic response, and post-exercise recovery time. Baseline associations with AHI were examined using multivariable linear regression, and longitudinal changes were assessed using linear mixed-effects models. Higher baseline AHI was independently associated with lower HRR1, HRR4, and chronotropic response (all p < 0.05), independent of ESS. During follow-up, HRR1, HRR4, and chronotropic response showed no meaningful change, whereas recovery time shortened significantly over time (p < 0.01). Longitudinal trajectories did not differ by sleepiness status. OSA severity is linked to impaired autonomic capacity, while CPAP therapy selectively improves autonomic recovery dynamics. Sleepiness does not modify these adaptations, suggesting that CPAP enhances autonomic flexibility rather than reversing established autonomic impairment.
8 April 2026 in Annals of the American Thoracic Society
Rationale: Recent randomized controlled trials failed to show cardiovascular benefits of treating obstructive sleep apnea (OSA) in intention-to-treat analyses which has been a matter of debate since publication of the results. Objectives: To address whether untreated OSA persists after one year in adults with coronary artery disease (CAD) following revascularization and to explore whether major cardiovascular and cerebrovascular events (MACCEs) differ between the patients who persist vs improve in OSA severity. Measurements: The study population included 119 CAD patients with moderate to severe OSA from the RICCADSA trial. All participants had an apnea-hypopnea index (AHI) ≥ 15/h and were randomized to no continuous positive airway pressure (CPAP) therapy (n = 81) or were not using the device (n = 38). Patients without OSA (AHI < 5/h) at baseline (n = 85) were included as a control group. Home sleep apnea tests were performed at baseline and after one year. Main Results: The median AHI decreased from 24.5 (19.4-36.0/h) to 15.1 (8.2-27.3/h) and Oxygen Desaturation Index (4%) decreased from 14.8 (7.3-22.9/h) to 6.6/h (2.7-14.4/h) after one year (P < .001 for both). In all, 73 (61.3%) improved in OSA severity (59 had AHI 5-14.9/h and 14 had AHI < 5/h) whereas 46 (38.7%) had persistent OSA. The control group had a median AHI 4.4 (2.9-7.9/h) after one year. N-Terminal Pro-B-Type Natriuretic Peptide values decreased significantly in the overall cohort, with similar directional trends across OSA trajectory groups. The patients with improvement in OSA had significantly lower risk for MACCEs (Hazard Ratio 0.25, %95 CI 0.08-0.76; P = .015) compared to the patients with persistent OSA. Conclusions: Most of the CAD patients with moderate to severe OSA improve in OSA severity one year after revascularization, probably due to the improved cardiac function, and have a decreased risk for MACCEs compared to individuals with persistent OSA. Identifying patients with persistent OSA after revascularization may help target those most likely to benefit from focused intervention, particularly in settings where CPAP therapy is not initiated or is poorly tolerated.
29 June 2026 in Clinical Cardiology
Background: Heart failure with preserved ejection fraction (HFpEF) is closely linked to aging and cardiometabolic risk factors and frequently coexists with obstructive sleep apnea (OSA). We aimed to investigate the prevalence and clinical correlates of an HFpEF‐like phenotype in a revascularized coronary artery disease (CAD cohort), focusing on OSA and its severity. Methods: A total of 435 patients with preserved left ventricular ejection fraction from the RICCADSA cohort were included. OSA was defined as apnea–hypopnea index (AHI) ≥ 15 events/h. HFpEF‐like phenotype was defined by ≥ 2 of the following: elevated filling pressures (E/e′ ≥ 15), left atrial enlargement, increased left ventricular mass index, elevated pulmonary artery systolic pressure (≥ 35 mmHg), and elevated NT‐proBNP (≥ 125 pg/mL). Multivariable logistic regression analyses included age, sex, obesity, hypertension, diabetes, and OSA status. Additional models evaluated AHI and oxygen desaturation index (ODI) as continuous variables and assessed the impact of excluding body mass index (BMI). Results: Mean age was 63.6 ± 8.6 years and BMI 28.1 ± 4.1 kg/m 2 ; 69.9% met HFpEF‐like criteria. Age and obesity were independently associated with HFpEF‐like phenotype, whereas categorical OSA was not. AHI and ODI were not independently associated after adjustment; however, in models excluding BMI, both AHI (OR 1.019, 95% CI 1.005–1.033) and ODI (OR 1.030, 95% CI 1.010–1.050) were significant predictors. Conclusions: HFpEF‐like phenotype is highly prevalent in CAD and primarily associated with aging and adiposity. The relationship between OSA severity and cardiac remodeling appears dependent on obesity, underscoring the interplay between cardiometabolic and sleep‐related factors. Pre‐registered Clinical Trial Number: The RICCADSA trial is registered at ClinicalTrials.gov (NCT00519597) and in the Swedish national research registry (FoU i Sverige—Research and Development in Sweden; registration no. VGSKAS‐4731; April 29, 2005).